

Amendments to the Claims:

The listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

1-35. (Canceled)

36. (Currently Amended) A pharmaceutical composition comprising a human or canine replication defective recombinant adenovirus comprising:
a suicide gene operably linked to a promoter controlling expression of the gene in infected cells;

a left and a right inverted terminal repeat (ITR); and
an encapsidation signal,
wherein the adenovirus is impregnated in a hydrogel in an amount effective for inhibiting a decrease in luminal diameter of an atheromatous blood vessel when administered to a site of physical damage to said blood vessel.

37. (Currently Amended) The pharmaceutical composition of claim [[37]] 36,
wherein the adenovirus infects at least 0.2% of smooth muscle cells of the neointima.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

38. (Canceled)

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

39. (Currently Amended) A device for percutaneous administration of a therapeutic suicide gene, said device comprising a balloon catheter coated with a hydrogel impregnated with a human or canine defective recombinant adenovirus comprising:

said gene operably linked to a promoter controlling expression of the gene in infected cells;

a left and a right inverted terminal repeat (ITR); and

an encapsidation signal,

wherein said defective recombinant adenovirus is present in an amount effective for inhibiting a decrease in luminal diameter of an atheromatous blood vessel when administered to a site of physical damage to said blood vessel.

40-44. (Canceled)

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com